KRAS and familial pancreatic carcinoma: KrasG12D is required for both the initiation and maintenance processes of pancreatic cancer in mouse models, and was shown to be the most common oncogenic KRAS mutation presented in more than 90% of human PDAC, leading to a dominant and constitutively active form of GTPase [69,70].